The impact of ixekizumab treatment for psoriasis on cardiovascular-related parameters in patients is unknown., Ixekizumab maintenance dosing (12-60-weeks) had a neutral impact on cardiovascular-related parameters (including total cholesterol, LDL-cholesterol, HDL-cholesterol, LDL/HDL, triglycerides), Ixekizumab's neutral impact on cardiovascular-related parameters should not alter decisions to treat with other medications/interventions targeting cardiovascular-related parameters.
Τρίτη 13 Μαρτίου 2018
Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: results from UNCOVER-1, -2, and -3
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Small molecule inhibitor of the Wnt pathway (SM04755) as a potential topical treatment for psoriasisBackground: Psoriasis (PSO) is an autoimmune disease causing patches of thick, inflamed, scaly skin due to excessive proliferation of skin c...
-
Clinical and animal studies show that ethanol exposure and inflammation during pregnancy cause similar behavioral disturbances in the offspr...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.